A guide for reporting the results of population pharmacokinetic analyses: A Swedish perspective
Journal Title: The AAPS Journal - Year 2005, Vol 7, Issue 2
Abstract
Population pharmacokinetic analyses are frequently part of regulatory submissions and are mainly used to provide information on special populations (effects of age, renal impairment, etc) and drug-drug interactions. A varying standard of population analysis reports has been received at the Medical Products Agency in Sweden, some very good and some unassessable. In the latter case, it may be that it is a report of an inadequate analysis or may be a report of a perfectly acceptable analysis, but too little detail has been provided in the report for the conclusions reached to be properly assessed. A sufficient level of detail must be present in these reports in order for them to be assessable and to allow the conclusions reached to be incorporated into the summary of product characteristics. The report should specify the goal(s) of the analysis, describe in detail the origin and nature of the data, clearly describe the model-building process, include a range of goodness of fit (GOF) plots to support decisions made during the model-building process, and demonstrate that the final model is a good description of the data. The use of color in GOF plots is encouraged so that key features are easily visible. Covariate effects in the final model should be clearly presented and their clinical relevance discussed. In the case of many covariates in the final model, it may be useful to perform some simulations to illustrate the effect of various covariate combinations for a series of different “typical” subjects.
Authors and Affiliations
Janet R. Wade, Monica Edholm, Tomas Salmonson
Keywords
Related Articles
- EP ID EP681878
- DOI 10.1208/aapsj070245
- Views 99
- Downloads 0
Challenges and Opportunities in Achieving Bioequivalence for Fixed-Dose Combination Products
Fixed-dose combination (FDC) products are becoming a popular treatment option because of increased patient compliance and convenience, improved clinical effectiveness, and reduced cost to the patient, among several other...
Rationalizing Structure and Target Relationships between Current Drugs
A recent analysis of structure and target relationships between current drugs and bioactive compounds has revealed that only a small fraction of drugs that are active against the same or overlapping targets are involved...
From Target Selection to the Minimum Acceptable Biological Effect Level for Human Study: Use of Mechanism-based PK/PD Modeling to Design Safe and Efficacious Biologics
The online version of this article (doi:10.1208/s12248-011-9256-y) contains supplementary material, which is available to authorized users.
Application of dense gas techniques for the production of fine particles
The feasibility of using dense gas techniques such as rapid expansion of supercritical solutions (RESS) and aerosol solvent extraction system (ASES) for micronization of pharmaceutical compounds is demonstrated. The chir...
Recent Advances in Blood–Brain Barrier Disruption as a CNS Delivery Strategy
The blood–brain barrier (BBB) is a complex functional barrier composed of endothelial cells, pericytes, astrocytic endfeets and neuronal cells. This highly organized complex express a selective permeability for m...